Vector-based vaccines use a harmless virus to deliver genetic instructions for a pathogen antigen. When people have preexisting immunity to the vector, shaped by prior infection or exposure, immune responses that recognize the vector can reduce antigen delivery and blunt the vaccine-induced immune response. This phenomenon is important for efficacy, safety, and the design choices that developers make.
Mechanisms that reduce efficacy
Neutralizing antibodies directed at the vector coat prevent the vector from entering target cells, reducing antigen expression and lowering the magnitude of the desired immune response. Cellular immunity directed at vector-infected cells can accelerate clearance of those cells before they produce sufficient antigen. Both antibody-mediated neutralization and vector-specific T cell responses therefore limit vaccine "take" and can cause more rapid waning of protection. Evidence from the HIV Step trial reported by Stephen P. Buchbinder Fred Hutchinson Cancer Research Center and colleagues showed that an adenovirus serotype 5 vector failed to protect and raised concerns about interactions between vector immunity and clinical outcomes. These results illustrate how vector immunity can alter both immunogenicity and population-level effects.
Practical consequences and mitigations
Because preexisting immunity differs across populations, vaccine performance can vary territorially and culturally where exposure to common human adenoviruses is higher. This geographic variation has public health implications for deployment strategies in regions with high vector seroprevalence. To address this, developers such as Sarah Gilbert University of Oxford and Adrian V. S. Hill University of Oxford selected nonhuman adenovirus platforms or rare human serotypes to circumvent common immunity. Other strategies include increasing dose, using heterologous prime-boost regimens that mix different vectors, or switching to nonviral platforms like mRNA where vector immunity is not relevant.
Understanding vector immunity is essential for regulatory assessments, real-world effectiveness monitoring, and informed consent in communities with distinct exposure histories. The impact is not uniform; it depends on vector type, population serostatus, and the immune response needed to protect against the target disease. Clear reporting of seroprevalence, immunogenicity by baseline vector immunity, and post-licensure effectiveness across diverse settings improves trust and guides equitable vaccine use.